Tagged Articles

Actos 310 articles

Novel new diabetes treatment fares well in clinical trials

Clinical trials on a novel new type 2 diabetes treatment lowered glucose, did not increase lipids, and was well tolerated in patients with the chronic disease. The drug is an investigative liver-selective glucokinase activator, or GK activator, referred to as TTP399. It is a key regulator of glucose homeostasis. It is a member of the Hexokinase family and is expressed in the endocrine cells of the Langerhans islets of the liver, in the L- and K-cells of the intestines, and in the neurons of the central nervous system, in particular the hypothalamus. GK modulates blood glucose by inducing glucose-stimulated insulin ... Read More

FDA orders post-market studies on newly approved type 2 diabetes drug Jardiance

Jardiance (empagliflozin), a new type 2 diabetes drug, has been granted approval by the U.S. Food and Drug Administration (FDA). The medication can be used alone or added to existing treatment regimens to control blood sugar levels. Jardiance, made by Boehringer Ingelheim, is in a class of drugs called sodium glucose co-transporter 2 (SGLT2) inhibitors. These drugs work by stopping blood sugar from becoming reabsorbed by the kidneys. Thus, more glucose is excreted by the kidneys, which lowers blood sugar levels. Other SGLT2 drugs include Invokana (canagliflozin) and Farxiga (dapagliflozin). The FDA approved Jardiance based on a review of seven ... Read More

Waistline measurement can indicate type 2 diabetes risk

Want to know if you are at risk for type 2 diabetes? Then whip out your tape measure, says Public Health England. Waistlines larger than 40 inches in men or 35 inches in women indicate a “very high risk” of developing the chronic disease, the agency warns. Men with a 40-inch waist are five times more likely to develop type 2 diabetes and women with 35-inch waistlines were three times more likely to develop the disease compared to those with slimmer waistlines. Even waistlines three to four inches smaller than 40 or 35 inches for men and women, respectively, puts ... Read More

Controversial analysis suggests Actos may help protect users from dementia

The type 2 diabetes drug Actos could help ward off dementia, a new analysis has found. However, researcher say more analysis is needed as well as adverse side effects addressed before the medication can be recommended as a preventative measure. The analysis involved data from Germany’s biggest public health insurer, which included about 146,000 patients aged 60 or older. The patients were tracked from 2004 to 2010, during which time about 14,000 of them developed dementia. When prescriptions for Actos were factored into the analysis, researchers found that patients taking Actos had about a 6 percent decline in the likelihood ... Read More

Pre-diabetes diagnoses benefit drug companies more than patients

Non-diabetics with higher-than-recommended blood sugar levels and thus at risk for developing type 2 diabetes are considered pre-diabetic, however classifying large numbers of people with pre-diabetes offers more benefit to drug companies than those diagnosed with the condition, researchers argue. In an editorial published in the British Medical Journal, researchers with University College London and the Mayo Clinic in Minnesota said that labeling people as pre-diabetic increases the likelihood that they will be prescribed medication prematurely, which would at best only briefly delay the onset of illness. It would also prematurely expose them to potential side effects from the drugs. John ... Read More

Healthier diabetics may fare better with less aggressive approach to disease management

Type 2 diabetes drugs could be doing patients more harm than good, especially older diabetics, a new study shows. The research, published in a recent edition of the Journal of the American Medical Association Internal Medicine, addressed how current guidelines for diabetes management were serving patients. Currently, diabetes management involves intensifying treatment until the patient’s blood sugar level has evened out. Researchers say this method appears to cause more negative impacts to patients than positive ones. “For people with type 2 diabetes, the goal of managing blood sugar levels is to prevent associated diabetes complications, such as kidney, eye and ... Read More

FDA approves inhaled insulin for type 2 diabetes

After a three-year delay, the Food and Drug Administration (FDA) has granted approval of an inhaled insulin to treat type 2 diabetes. MannKind Corp’s drug Afrezza is a fast-acting form of insulin in a form of a powder that comes in a single-use cartridge. It is designed to be inhaled at the start of a meal or within 20 minutes of starting. Patients using the drug can achieve peak insulin levels within 12 to 15 minutes – much faster than the 90 minutes it generally takes with injectable insulin. Afrezza is not a substitute for long-acting insulin, but is a ... Read More

FDA finds cardiovascular risk with blood pressure medication used by diabetics is inconclusive

There is no clear evidence that the blood pressure medication olmesartan increases the risk of cardiovascular events in diabetic patients, the Food and Drug Administration (FDA) said in a Drug Safety Communication. The FDA began a safety review of olmesartan in 2010 after results from the ROADMAP (Randomized Olmesartan and Diabetes Microalbuminuria Prevention) clinical trial raised cardiovascular risk concerns. The clinical trial was designed to see whether olmesartan could delay kidney damage in patients with type 2 diabetes. There was an unexpected finding of an increased risk of cardiovascular death in patients treated with olmesartan compared to patients given a ... Read More

More drugs in development to treat ailments of an increasing aging population

Americans are living longer and as a result, the number of people 65 years of age and older with serious chronic conditions is also increasing. Pharmaceutical companies are rushing to cash in by developing drugs to treat the nearly 50 million Medicare beneficiaries who are battling conditions such as diabetes, high cholesterol, high blood pressure, and osteoarthritis. Currently, about 435 drugs primarily targeting seniors are either in clinical trials or under review by the Food and Drug Administration (FDA), according to a report by the Pharmaceutical Research and Manufacturers of America. Among them, 110 are designed to treat diabetes, 68 ... Read More

Number of diabetics continues to escalate year after year

The rate of diabetes and pre-diabetes in the United States continues to rise dramatically, so much so that the Centers for Disease Control and Prevention (CDC) warns one in every three Americans will have the condition by 2050. The new National Diabetes Statistics Report estimates that from 2010 to 2012, the number of adults with diabetes jumped from 26 million to nearly 30 million, and that a quarter of those individuals don’t know they have the disease. Uncontrolled diabetes can cause serious complications including heart disease, kidney disease, blindness, and amputations due to neuropathy. Also alarming is that another 86 ... Read More